ABT-263, Bcl-2 family inhibitor, Senolytic agent

Product Details

Formal Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)- 3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]-phenyl]sulfonyl]-benzamide

Alternate Names: Navitoclax

Molecular Formula: C₄₇H₅₅ClF₃N₅O₆S₃

Formula Weight: 974.6

CAS Number: 923564-51-6

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 25 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.

Applications

Bcl-2 family inhibitor, Senolytic agent

Functions

Potent and selective Bcl-2 family inhibitor / BH3 domain mimetic which binds to Bcl-2, Bcl-xL and Bcl-w (Ki<1 nM).  A useful tool compound which has shown interesting results in various cancer clinical trials. Synergizes with deoxyglucose and other agents, inducing apoptosis in cancer cells in a xenograft mouse model.  A novel senolytic agent, inducing apoptosis preferentially in senescent cells in a cell type-restricted manner.

Application Procedures

First dissolved in DMSO (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20° for up to 3 months.

Research use only.

Documents

• Datasheet (PDF)